(Reuters) – Cytokinetics Inc said on Tuesday the U.S health regulator declined to approve its oral drug for a type of heart failure, citing lack of sufficient data to show the drug was effective. The U.S. Food and Drug Administration’s decision comes after a panel of outside experts in December recommended against allowing the use of the drug due to safety concerns.
(Reporting by Pratik Jain and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
